9P5I | pdb_00009p5i

E. coli Dihydropteroate Synthase in complex with pterin-based inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.14 Å
  • R-Value Free: 
    0.238 (Depositor), 0.238 (DCC) 
  • R-Value Work: 
    0.192 (Depositor), 0.192 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Development of Pyrimido Pyridazine Analogs through Increased Whole Cell Target Engagement of the Dihydropteroate Synthase Pterin Binding Site in Gram-Negative Bacteria.

Snoke, H.E.Reeve, S.M.Dharuman, S.Wallace, M.J.Loudon, V.C.Zhao, Y.Bowling, J.J.Murphy, P.A.Waddell, B.Lee, R.B.Bulitta, J.B.Lee, R.E.

(2025) ACS Infect Dis 11: 3237-3250

  • DOI: https://doi.org/10.1021/acsinfecdis.5c00635
  • Primary Citation of Related Structures:  
    9P4A, 9P5I

  • PubMed Abstract: 

    Dihydropteroate synthase (DHPS) is a critical enzyme in the folate biosynthetic pathway of bacteria, fungi, and protozoans. Sulfonamides successfully target the p- aminobenzoic acid ( p ABA) binding site of DHPS, forming a false product that obstructs the formation of 7,8-dihydropteroate and disrupts subsequent reactions in the pathway. Pyrimido[4,5- c ]pyridazine-based inhibitors target the pterin binding site of DHPS, demonstrating high target affinity but minimal antimicrobial activity, which has previously been attributed to poor permeability without detailed analysis. In this study, we investigate the permeability limitations of our pyrimido pyridazine series in Gram-negative bacteria within the context of whole cell target engagement and cellular accumulation. To evaluate their whole cell target engagement against Escherichia coli DHPS ( Ec DHPS), we developed a robust luminescence-based HiBiT cellular thermal shift assay and combined it with surface plasmon resonance and an LC-MS/MS-based accumulation assay. This orthogonal assay platform was used to reevaluate the SAR of our Legacy pyrimido pyridazine compound series against Ec DHPS and to facilitate the design of an exploratory series of compounds with improved permeability. From this series, we found that the removal or replacement of the negatively charged carboxylic acid pyrimido pyridazine side chain with a thiotetrazole or a nitrile group resulted in increased accumulation, improved whole cell target engagement, and moderate antimicrobial activity against E. coli .


  • Organizational Affiliation
    • Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38103, United States.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Dihydropteroate synthase
A, B
277Escherichia coliMutation(s): 0 
Gene Names: folPdhpSb3177JW3144
EC: 2.5.1.15
UniProt
Find proteins for P0AC13 (Escherichia coli (strain K12))
Explore P0AC13 
Go to UniProtKB:  P0AC13
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP0AC13
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1CG7 (Subject of Investigation/LOI)
Query on A1CG7

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
7-amino-1-methyl-3-{[(1H-tetrazol-5-yl)amino]methyl}pyrimido[4,5-c]pyridazine-4,5(1H,6H)-dione
C9 H10 N10 O2
HPEOIAAOXXIKAO-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.14 Å
  • R-Value Free:  0.238 (Depositor), 0.238 (DCC) 
  • R-Value Work:  0.192 (Depositor), 0.192 (DCC) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 43.721α = 90
b = 94.551β = 90
c = 136.846γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
Aimlessdata scaling
Cootmodel building
REFMACphasing
XDSdata reduction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)United StatesR01AI136803

Revision History  (Full details and data files)

  • Version 1.0: 2025-11-05
    Type: Initial release
  • Version 1.1: 2025-11-26
    Changes: Database references